The incidence of hepatocellular carcinoma (HCC) in patients with primary biliary cirrhosis (PBC) is not well known. The aims of this study are to determine HCC incidence and survival, and to identify risk factors associated with these outcomes in patients with PBC. We collected information on 396 patients with PBC at enrollment and followed-up from 6 to 271 months. They were all negative for hepatitis B and C virus markers. HCC was detected by scanning with ultrasonography, computed tomography, or both every 4 to 6 months. Life expectancy (LE) was approximated with the declining exponential approximation of LE. A total of 14 patients developed HCC. The cumulative appearance rate of HCC in patients with advanced-stage PBC (Scheuer's stage III or IV) was significantly higher than that for patients with early-stage (stage I or II) (12.3% and 7.7% by the tenth year, respectively. P ؍ .021). Proportional hazards analysis showed 3 factors are independently associated with the development of HCC: age at the time of diagnosis, male gender, and history of blood transfusion. Age, male gender, and advanced-stage PBC were associated with survival, but HCC development was not. The disease-specific annual mortality rate was estimated to be 0.008 for women and 0.028 for men with advanced-stage PBC. In conclusion, HCC develops in old patients with advanced-stage PBC, but HCC does not affect the patients' survival. P rimary biliary cirrhosis (PBC) is a chronic liver disease of unknown etiology presenting a variety of disease spectrum from asymptomatic disease state to full-blown cirrhosis. Patients with liver cirrhosis caused by chronic infection of hepatitis C virus (HCV) or hepatitis B virus (HBV) are at high risk of hepatocellular carcinoma (HCC); however, it is not known whether the HCC incidence is high in patients with PBC. Although there are 9 studies about HCC incidence in PBC, the results are not consistent. 1-9 Some studies 3,4 show that patients with PBC have no excess risk of developing HCC and others [5][6][7][8][9] show that the incidence of HCC is high in those patients. An Italian study indicated that HCC has a relatively high prevalence in PBC and HCV superinfection may play an important part in favoring HCC. 7 Even though without HBV or HCV infection, a study conducted in UK showed 5.9% of patients with PBC in precirrhotic or cirrhotic stage had developed HCC. 6 The authors of this large-scale cohort study concluded that men with advanced-stage PBC have a higher risk of developing HCC. A recent retrospective study in the Mayo Clinic also reported that patients with PBC 8 are at high risk of hepatobiliary malignancies but the authors did not mention risk factors for HCC development.The aims of the present study are to analyze the survival of patients with PBC, to quantify the incidence at which they develop HCC, and to identify HCC risk factors. In addition, we determined whether HCC affected the survival of patients with PBC. Therefore, we tested 2 hypotheses: (1) that the patients with advanced-stage PBC sur...
In patients with chronic hepatitis C; combined interferon and cyclosporin A treatment was more effective than interferon monotherapy. The benefit was mostly achieved in patients with a high viral load and HCV genotype 1.
Fulminant hepatic failure (FHF) is characterized by massive necroinflammation of the liver tissue and is associated with high mortality. Serum concentrations of IL-1 beta, tumour necrosis factor-alpha (TNF-alpha), IL-6 and IL-1 receptor antagonist (IL-1Ra) were measured in 30 patients with FHF and in 23 patients with acute hepatitis (AH) before start of treatment and in 23 healthy controls. Levels of all four molecules were increased significantly in FHF compared with AH, in which values were higher than in the healthy controls. High serum levels of IL-1 beta and a significantly reduced ratio of IL-1Ra to IL-1 beta (IL-1Ra/IL-1 beta) were observed in FHF patients who subsequently died compared with subjects who survived. TNF-alpha and IL-6 concentrations were correlated with levels of human hepatocyte growth factor (hHGF), an index of hepatocyte regeneration. Although serum cytokine levels varied considerably between patients within each group studied, it is suggested that the striking elevation in proinflammatory cytokine levels in FHF may reflect both the insufficiency of hepatitis virus elimination and a failure to control a vicious cytokine cascade leading to overwhelming hepatocyte destruction rather than regeneration. The high cytokine levels observed in these patients and the significantly elevated IL-1Ra/IL-1 beta ratio in FHF patients who survived compared with those who did not suggest the possible therapeutic use of cytokine antagonists for the control of this life-threatening disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.